[go: up one dir, main page]

DK2189162T3 - Fremgangsmåder til behandling af cellulære proliferative forstyrrelser - Google Patents

Fremgangsmåder til behandling af cellulære proliferative forstyrrelser

Info

Publication number
DK2189162T3
DK2189162T3 DK10153374.3T DK10153374T DK2189162T3 DK 2189162 T3 DK2189162 T3 DK 2189162T3 DK 10153374 T DK10153374 T DK 10153374T DK 2189162 T3 DK2189162 T3 DK 2189162T3
Authority
DK
Denmark
Prior art keywords
treatment
methods
proliferative disorders
cellular proliferative
cellular
Prior art date
Application number
DK10153374.3T
Other languages
English (en)
Inventor
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of DK2189162T3 publication Critical patent/DK2189162T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/765Reovirus; Rotavirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/115Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135Respiratory syncytial virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/14Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
DK10153374.3T 2000-11-09 2001-10-26 Fremgangsmåder til behandling af cellulære proliferative forstyrrelser DK2189162T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24672800P 2000-11-09 2000-11-09
EP01980092A EP1332366B1 (en) 2000-11-09 2001-10-26 Methods for the Assessment of Cellular Proliferative Disorders

Publications (1)

Publication Number Publication Date
DK2189162T3 true DK2189162T3 (da) 2014-02-03

Family

ID=22931950

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01980092.9T DK1332366T3 (da) 2000-11-09 2001-10-26 Fremgangsmåde til vurdering af cellulære proliferative forstyrrelser
DK10153374.3T DK2189162T3 (da) 2000-11-09 2001-10-26 Fremgangsmåder til behandling af cellulære proliferative forstyrrelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK01980092.9T DK1332366T3 (da) 2000-11-09 2001-10-26 Fremgangsmåde til vurdering af cellulære proliferative forstyrrelser

Country Status (17)

Country Link
US (3) US7052832B2 (da)
EP (2) EP1332366B1 (da)
JP (2) JP4146725B2 (da)
AR (1) AR031281A1 (da)
AT (1) ATE472733T1 (da)
AU (2) AU2002212022B2 (da)
BR (1) BR0115235A (da)
CA (1) CA2428206C (da)
DE (1) DE60142485D1 (da)
DK (2) DK1332366T3 (da)
ES (2) ES2445704T3 (da)
HK (1) HK1142833A1 (da)
IL (1) IL154881A0 (da)
MX (1) MXPA03004029A (da)
NZ (1) NZ524937A (da)
WO (1) WO2002039117A1 (da)
ZA (1) ZA200302086B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US7306902B2 (en) * 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
US20040115170A1 (en) * 2001-11-30 2004-06-17 Brown Earl Garnet Oncolytic virus
AR053272A1 (es) * 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
WO2007093036A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
WO2008031230A1 (en) * 2006-09-15 2008-03-20 Dalhousie University Methods of determining susceptibility of cells to reovirus infection and methods for treating cellular proliferative disorders with reovirus
CA2678721C (en) * 2007-03-12 2018-02-13 Oncolytics Biotech Inc. Reoviruses having modified sequences
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos
CA2699805A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
TWI399369B (zh) 2008-04-02 2013-06-21 Nat Defense Medical Ct 咪唑蒽醌衍生物及其合成方法
JP2011520994A (ja) * 2008-05-27 2011-07-21 オンコリティクス バイオテク,インコーポレーテッド 腫瘍崩解性レオウイルス療法中の炎症性サイトカイン産生の排除
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
US20180305345A1 (en) 2015-01-26 2018-10-25 Ottawa Hospital Research Institute Compositions and methods for enhancing oncolytic virus efficacy
CN110022889B (zh) 2016-10-03 2024-05-10 渥太华医院研究所 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法
CA2971832A1 (en) * 2017-06-23 2018-12-23 Roy Duncan Recombinant oncolytic viruses for treatment of metastatic cancers
AU2018373508A1 (en) 2017-11-24 2020-04-30 Ottawa Hospital Research Institute Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders

Also Published As

Publication number Publication date
ATE472733T1 (de) 2010-07-15
CA2428206C (en) 2005-09-27
US7815914B2 (en) 2010-10-19
AU1202202A (en) 2002-05-21
EP1332366A1 (en) 2003-08-06
US7052832B2 (en) 2006-05-30
HK1142833A1 (en) 2010-12-17
IL154881A0 (en) 2003-10-31
JP4146725B2 (ja) 2008-09-10
US20080057073A1 (en) 2008-03-06
CA2428206A1 (en) 2002-05-16
US20060172288A1 (en) 2006-08-03
NZ524937A (en) 2004-10-29
JP2008268200A (ja) 2008-11-06
ZA200302086B (en) 2004-03-15
MXPA03004029A (es) 2004-02-12
JP2004512385A (ja) 2004-04-22
DK1332366T3 (da) 2010-08-02
ES2445704T3 (es) 2014-03-04
BR0115235A (pt) 2003-10-14
WO2002039117A1 (en) 2002-05-16
AU2002212022B2 (en) 2006-03-30
ES2347523T3 (es) 2010-11-02
DE60142485D1 (de) 2010-08-12
US20020086284A1 (en) 2002-07-04
EP1332366B1 (en) 2010-06-30
US7763252B2 (en) 2010-07-27
AR031281A1 (es) 2003-09-17
EP2189162A1 (en) 2010-05-26
EP2189162B1 (en) 2013-11-27

Similar Documents

Publication Publication Date Title
DK1156813T3 (da) Reovirus til behandling af cellulære proliferative lidelser
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK2189162T3 (da) Fremgangsmåder til behandling af cellulære proliferative forstyrrelser
DK1343773T3 (da) Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
DK1147083T3 (da) Arylpiperazinyl-cyclohexylindolderivater til behandling af depression
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DK1144395T3 (da) 2-amino-benzoxazinon-derivater til behandling af fedme
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
IL153846A0 (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
DK0967214T3 (da) Intranasale formuleringer til behandling af seksuelle forstyrrelser
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1997512T3 (da) Fremgangsmåder til behandling af TWEAK-relaterede tilstande
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
DK1499730T3 (da) Immunokonjugater til behandling af tumorer
DK1282616T3 (da) Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DK1345598T3 (da) Anvendelsen af rosiglitazon til behandling af psykiatriske lidelser
DK1344526T3 (da) Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
DK1350521T3 (da) Immunoterapeutiske kombinationer til behandling af tumorer
DK1292586T3 (da) Fremgangsmåde til fremstilling af pyrazolopyrimidinoner
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1257278T3 (da) Anvendelse af mirtazapin til behandling af sövnforstyrrelser